Bristol-Myers Squibb stock (US0897961004): FY 2026 guidance and institutional positioning shifts

Bristol-Myers Squibb raised full-year 2026 EPS guidance to 6.05–6.35 as Q1 revenue grew 2.6% year-over-year, while major institutional investors adjusted their positions in the pharmaceutical giant.

Bristol-Myers Squibb Company reported first-quarter 2026 results with revenue growth of 2.6% compared to the same period last year, according to MarketBeat as of May 11, 2026. The company has set its full-year 2026 earnings per share guidance at 6.05–6.35, providing investors with a clear earnings trajectory for the remainder of the fiscal year.

As of: May 11, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bristol Myers Squibb Company
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: United States
• Core markets: Global pharmaceutical markets, oncology, immunology, cardiovascular
• Key revenue drivers: Branded pharmaceutical products, specialty medicines
• Home exchange/listing venue: NYSE (BMY)
• Trading currency: USD
• Return on equity: 64.87%
• Net margin: 15.01%

Bristol-Myers Squibb: core business model

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines across oncology, immunology, cardiovascular disease, and cell therapy. The company operates through a diversified portfolio of branded pharmaceutical products and maintains a significant presence in the United States and international markets. With a net margin of 15.01% and return on equity of 64.87%, the company demonstrates strong profitability metrics within the pharmaceutical sector, which is critical for US investors evaluating exposure to large-cap healthcare stocks.

Q1 2026 financial performance and full-year guidance

The company's first-quarter revenue increased 2.6% year-over-year, reflecting steady demand for its pharmaceutical portfolio, according to MarketBeat as of May 11, 2026. Bristol-Myers Squibb has guided full-year 2026 earnings per share in the range of 6.05–6.35, providing a midpoint of approximately 6.20 EPS. This guidance reflects management's confidence in the company's ability to sustain revenue growth and manage operating expenses throughout the fiscal year, a key metric for equity investors assessing earnings trajectory.

Institutional investor activity

Securian Asset Management Inc. reduced its stake in Bristol-Myers Squibb by 43.7% during the fourth quarter, according to its most recent Securities and Exchange Commission filing disclosed on May 11, 2026. Simultaneously, Swiss Life Asset Management Ltd. acquired shares in the company during the same period. These institutional positioning shifts reflect ongoing portfolio rebalancing among major asset managers and may indicate changing risk assessments or allocation strategies within the pharmaceutical sector.

Conclusion

Bristol-Myers Squibb's first-quarter 2026 results demonstrate modest revenue growth of 2.6% year-over-year, supported by full-year EPS guidance of 6.05–6.35. The company's strong profitability metrics—including a 64.87% return on equity and 15.01% net margin—underscore its position as a significant player in the global pharmaceutical market. Institutional investor activity, including position reductions and acquisitions, reflects the dynamic nature of large-cap healthcare holdings. US investors monitoring Bristol-Myers Squibb should track quarterly earnings performance, guidance updates, and pipeline developments as key indicators of future stock performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.